DOCSLIB.ORG

Råvarer, DLS 2019.0 Ph.Eur

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Råvarer, DLS 2019.0 Ph.Eur Råvarer, DLS 2019.0 / Ph.Eur. 9.6 Se: "Introduktion til fortegnelse over gældende standarder for råvarer" i tekstafsnittet. Alle ikke gældende synonymer er mærket med ° i fortegnelsen. Fed skrift: Navn på engelsk som angivet i Ph.Eur. Normal skrift: Dansk oversættelse. Abacavir sulfate Abacavirsulfat Ph.Eur. 8 th Ed., Suppl. 8.1 Absinthii herba° Wormwood Acacia Akaciegummi Ph.Eur. 8 th Ed., Suppl. 8.5 Acacia, spray-dried Akaciegummi, spraytørret Ph.Eur. 9 th Ed. Acaciae gummi dispersione Acacia, spray-dried desiccatum° Acaciae gummi° Acacia Acamprosate calcium Acamprosatcalcium Ph.Eur. 9 th Ed. Acanthopanacis gracilistyli Acanthopanax bark cortex° Acanthopanax bark Acanthopanax bark Ph.Eur. 9 th Ed., Suppl. 9.2 (2432) Acarbose Acarbose Ph.Eur. 9 th Ed. Acebutolol hydrochloride Acebutololhydrochlorid Ph.Eur. 9 th Ed. Aceclofenac Aceclofenac Ph.Eur. 9 th Ed. Acemetacin Acemetacin Ph.Eur. 9 th Ed. Acesulfame potassium Acesulfamkalium Ph.Eur. 9 th Ed. Acesulfamkalium Acesulfame potassium Ph.Eur. 9 th Ed. Acetazolamide Acetazolamid Ph.Eur. 9 th Ed. Acetic acid, glacial Eddikesyre, koncentreret Ph.Eur. 9 th Ed. Acetone Acetone Ph.Eur. 8 th Ed. Acetylcholine chloride Acetylcholinchlorid Ph.Eur. 8 th Ed. Acetylcysteine Acetylcystein Ph.Eur. 9 th Ed. Acetyldigoxin, β- Acetyldigoxin, ß- Ph.Eur. 8 th Ed. Acetylsalicylic acid Acetylsalicylsyre Ph.Eur. 9 th Ed. Acetylsalicylsyre Acetylsalicylic acid Ph.Eur. 8 th Ed. Acetyltryptophan, N - Acetyltryptophan, N - Ph.Eur. 9 th Ed. Acetyltyrosine, N - Acetyltyrosin, N - Ph.Eur. 9 th Ed. Achyranthes bidentata root Ph.Eur. 9 th Ed., Suppl. 9.7 (2999) Achyranthis bidentatae radix° Achyranthes bidentata root Aciclovir Aciclovir Ph.Eur. 8 th Ed. Acitretin Acitretin Ph.Eur. 9 th Ed., Suppl. 9.5 (1385) Adapalene Adapalen Ph.Eur. 9 th Ed. Adenine Adenin Ph.Eur. 9 th Ed. Adenosine Adenosin Ph.Eur. 8 th Ed. Adeps lanae cum aqua° Wool fat, hydrous Adeps lanae hydrogenatus° Wool fat, hydrogenated Ph.Eur. 9 th Ed. Adeps lanae° Wool fat Adeps solidus° Hard fat Adipic acid Adipinsyre Ph.Eur. 9 th Ed. Adipinsyre Adipic acid Ph.Eur. 8 th Ed. Adrenaline Adrenalin Ph.Eur. 8 th Ed. Adrenaline tartrate Adrenalintartrat Ph.Eur. 8 th Ed. Afrikansk blommebark Pygeum africanum bark Ph.Eur. 8 th Ed., Suppl. 8.3 Agar Agar Ph.Eur. 8 th Ed. Agermåneurt Agrimony Ph.Eur. 8 th Ed. Agni casti fructus° Agnus castus fruit Agnus castus fruit Kyskhedstræfrugt Ph.Eur. 8 th Ed., Suppl. 8.3 Agnus castus fruit dry extract Kyskhedstræfrugttørekstrakt Ph.Eur. 8 th Ed., Suppl. 8.3 Agrimoniae herba° Agrimony Agrimony Agermåneurt Ph.Eur. 8 th Ed. Air, medicinal Luft, medicinsk Ph.Eur. 8 th Ed. Air, synthetic medicinal Luft, syntetisk medicinsk Ph.Eur. 8 th Ed. Akaciegummi Acacia Ph.Eur. 8 th Ed., Suppl. 8.5 Akaciegummi, spraytørret Acacia, spray-dried Ph.Eur. 8 th Ed. Akebia stem Akebiastængel Ph.Eur. 9 th Ed., Suppl. 9.6 (2472) Akebiastængel Akebia stem Ph.Eur. 9 th Ed., Suppl. 9.6 (2472) Alanine Alanin Ph.Eur. 9 th Ed. Albendazole Albendazol Ph.Eur. 9 th Ed., Suppl. 9.6 (1386) Alchemilla Løvefod Ph.Eur. 8 th Ed. Alchemillae herba° Alchemilla Alcuronium chloride Alcuroniumchlorid Ph.Eur. 8 th Ed. Alexandrinsk sennesbælg Senna pods, Alexandrian Ph.Eur. 8 th Ed. Alfacalcidol Alfacalcidol Ph.Eur. 8 th Ed. Alfadex Alfadex Ph.Eur. 9 th Ed. Alfentanil hydrochloride Alfentanilhydrochlorid Ph.Eur. 8 th Ed. Alfuzosin hydrochloride Alfuzosinhydrochlorid Ph.Eur. 9 th Ed., Suppl. 9.1 (1287) Alginic acid Alginsyre Ph.Eur. 9 th Ed. Alginsyre Alginic acid Ph.Eur. 9 th Ed. Alimemazine hemitartrate Alimemazinhemitartrat Ph.Eur. 8 th Ed. Allantoin Allantoin Ph.Eur. 8 th Ed. Allii sativi bulbi pulvis° Garlic powder Allopurinol Allopurinol Ph.Eur. 9 th Ed. Almagate Almagat Ph.Eur. 9 th Ed. Almindelig gyldenris Goldenrod, European Ph.Eur. 8 th Ed. Almond oil, refined Mandelolie, renset Ph.Eur. 8 th Ed. Almond oil, virgin Mandelolie, jomfru Ph.Eur. 8 th Ed., Suppl. 8.3 Aloe barbadensis° Aloes, Barbados Aloe capensis° Aloes, Cape Aloe tørekstrakt, standardiseret Aloes dry extract, Ph.Eur. 8 th Ed., Suppl. 8.3 standardised Aloes dry extract, Aloe tørekstrakt, standardiseret Ph.Eur. 8 th Ed., Suppl. 8.3 standardised Aloes extractum siccum Aloes dry extract, standardised normatum° Aloes, Barbados Lægealoe Ph.Eur. 8 th Ed., Suppl. 8.3 Aloes, Cape Kapaloe Ph.Eur. 8 th Ed. Alprazolam Alprazolam Ph.Eur. 8 th Ed. Alprenolol hydrochloride Alprenololhydrochlorid Ph.Eur. 9 th Ed. Alprostadil Alprostadil Ph.Eur. 8 th Ed., Suppl. 8.4 Alteplase for injection Alteplase til parenteral Ph.Eur. 8 th Ed. anvendelse Alteplase til parenteral Alteplase for injection Ph.Eur. 8 th Ed. anvendelse Althaeae folium° Marshmallow leaf Althaeae radix° Marshmallow root Altizide Altizid Ph.Eur. 8 th Ed. Alttuberculin Tuberculin for human use, Ph.Eur. 8 th Ed. old Altæablad Marshmallow leaf Ph.Eur. 8 th Ed. Altæarod Marshmallow root Ph.Eur. 8 th Ed. Alum Alun Ph.Eur. 9 th Ed. Aluminium chloride Aluminiumchloridhexahydrat Ph.Eur. 9 th Ed. hexahydrate Aluminium hydroxide, Aluminiumhydroxidhydrat, til Ph.Eur. 9 th Ed. hydrated, for adsorption adsorbtion Aluminium magnesium Aluminiummagnesiumsilicat Ph.Eur. 8 th Ed. silicate Aluminium oxide, hydrated Aluminiumoxidhydrat Ph.Eur. 9 th Ed. Aluminium phosphate gel Aluminiumphosphatgel Ph.Eur. 9 th Ed. Aluminium phosphate, Aluminiumphosphathydrat Ph.Eur. 9 th Ed. hydrated Aluminium sodium silicate Natriumaluminiumsilikat Ph.Eur. 8 th Ed. Aluminium stearate Aluminiumstearat Ph.Eur. 8 th Ed. Aluminium sulfate Aluminiumsulfat Ph.Eur. 9 th Ed. Aluminiumhydroxidhydrat, til Aluminium hydroxide, Ph.Eur. 9 th Ed. adsorption hydrated, for adsorption Aluminiumoxidhydrat Aluminium oxide, hydrated Ph.Eur. 9 th Ed. Aluminiumphosphathydrat Aluminium phosphate, Ph.Eur. 9 th Ed. hydrated Alun Alum Ph.Eur. 9 th Ed. Alverine citrate Alverincitrat Ph.Eur. 9 th Ed. Amantadine hydrochloride Amantadinhydrochlorid Ph.Eur. 9 th Ed. Ambroxol hydrochloride Ambroxolhydrochlorid Ph.Eur. 9 th Ed. Amfetamine sulfate Amfetaminsulfat Ph.Eur. 8 th Ed. Amidotrizoic acid dihydrate Amidotrizoinsyredihydrat Ph.Eur. 9 th Ed. Amidotrizoinsyre° Amidotrizoic acid, dihydrate Amidotrizoinsyredihydrat Amidotrizoic acid dihydrate Ph.Eur. 9 th Ed. Amikacin Amikacin Ph.Eur. 8 th Ed., Suppl. 8.2 Amikacin sulfate Amikacinsulfat Ph.Eur. 9 th Ed., Suppl. 9.6 (1290) Amiloride hydrochloride Amiloridhydrochloriddihydrat Ph.Eur. 8 th Ed., Suppl. 8.6 dihydrate Aminobenzoesyre, 4- Aminobenzoic acid, 4- Ph.Eur. 9 th Ed. Aminobenzoic acid, 4- Aminobenzoesyre, 4- Ph.Eur. 9 th Ed. Aminocaproic acid Aminocapronsyre Ph.Eur. 9 th Ed. Aminocapronsyre Aminocaproic acid Ph.Eur. 9 th Ed. Aminoglutethimide Aminoglutethimid Ph.Eur. 9 th Ed. Amiodarone hydrochloride Amiodaronhydrochlorid Ph.Eur. 9 th Ed. Amisulpride Amisulprid Ph.Eur. 9 th Ed., Suppl. 9.6 (1490) Amitriptyline hydrochloride Amitriptylinhydrochlorid Ph.Eur. 9 th Ed. Amlodipine besilate Amlodipinbesilat Ph.Eur. 8 th Ed., Suppl. 8.7 Ammonia solution, Ammoniakopløsning, Ph.Eur. 9 th Ed. concentrated koncentreret Ammoniakopløsning, Ammonia solution, Ph.Eur. 9 th Ed. koncentreret concentrated Ammonio methacrylate Ammoniummethacrylat Ph.Eur. 9 th Ed., Suppl. 9.6 copolymer (type A) copolymer (type A) (2081) Ammonio methacrylate Ammoniummethacrylat Ph.Eur. 9 th Ed., Suppl. 9.6 copolymer (type B) copolymer (type B) (2082) Ammonium bromide Ammoniumbromid Ph.Eur. 9 th Ed. Ammonium chloride Ammoniumchlorid Ph.Eur. 9 th Ed. Ammonium glycyrrhizate Ammoniumglycyrrhizat Ph.Eur. 9 th Ed. Ammonium hydrogen Ammoniumhydrogencarbonat Ph.Eur. 9 th Ed. carbonate Ammoniummethacrylat Ammonio methacrylate Ph.Eur. 9 th Ed., Suppl. 9.6 copolymer (type A) copolymer (type A) (2081) Ammoniummethacrylat Ammonio methacrylate Ph.Eur. 9 th Ed., Suppl. 9.6 copolymer (type B) copolymer (type B) (2082) Amobarbital Amobarbital Ph.Eur. 8 th Ed. Amobarbital sodium Amobarbitalnatrium Ph.Eur. 8 th Ed. Amobarbitalnatrium Amobarbital sodium Ph.Eur. 8 th Ed. Amomi fructus° Amomum fruit Amomi fructus rotundis° Round amomum fruit Amomum fruit Intet dansk navn Ph.Eur. 8 th Ed., Suppl. 8.1 Amomum fruit, round Intet dansk navn Ph.Eur. 8 th Ed., Suppl. 8.1 Amoxicillin sodium Amoxicillinnatrium Ph.Eur. 9 th Ed. Amoxicillin trihydrate Amoxicillintrihydrat Ph.Eur. 8 th Ed. Amoxicillinnatrium Amoxicillin sodium Ph.Eur. 9 th Ed. Amorolfine hydrochloride Amorolfinhydrochlorid Ph.Eur. 9 th Ed. Amphotericin B Amphotericin B Ph.Eur. 8 th Ed. Ampicillin Ampicillin Ph.Eur. 9 th Ed. Ampicillin sodium Ampicillinnatrium Ph.Eur. 8 th Ed. Ampicillin trihydrate Ampicillintrihydrat Ph.Eur. 8 th Ed. Ampicillin, anhydrous Ampicillin, vandfri Ph.Eur. 8 th Ed. Ampicillin, vandfri Ampicillin, anhydrous Ph.Eur. 8 th Ed. Ampicillinnatrium Ampicillin sodium Ph.Eur. 8 th Ed. Amygdalae oleum raffinatum° Almond oil, refined Amygdalae oleum virginale° Almond oil, virgin Anastrozole Anastrozol Ph.Eur. 8 th Ed. Andrographidis herba° Andrographis herb Andrographis herb Kariyaturt Ph.Eur. 9 th Ed., Suppl. 9.3 (2712) Anemarrhena asphodeloides Anemarrhenajordstængel Ph.Eur. 8 th Ed., Suppl. 8.7 rhizome Anemarrhenajordstængel Anemarrhena asphodeloides Ph.Eur. 8 th Ed., Suppl. 8.7 rhizome Angelica root Angelikarod Ph.Eur. 8 th Ed. Angelica archangelica root Intet dansk navn Ph.Eur. 8 th Ed. Angelica dahurica root Angelica dahurica rod Ph.Eur. 9 th Ed., Suppl. 9.3 (2556) Angelica pubescens root Angelica pubescens rod Ph.Eur. 9 th Ed., Suppl. 9.3 (2557) Angelica sinensis root Angelikarod, kinesisk Ph.Eur. 9 th Ed., Suppl. 9.1 (2558) Angelicae radix° Angelica root Angelicae archangelicae radix° Angelica archangelica root Angelicae sinensis radix° Angelica sinensis root Angelikarod Angelica root Ph.Eur. 8 th Ed. Angelikarod, kinesisk Angelica sinensis root Ph.Eur. 9 th Ed., Suppl. 9.1 (2558) Animal epithelia and Dyreepitel og -udvækster til Ph.Eur. 9 th Ed. (2621) outgrowths for allergen allergenprodukter products Anis Aniseed Ph.Eur. 9 th Ed., Suppl. 9.2 (0262) Anise oil Anisolie Ph.Eur. 8 th Ed. Aniseed Anis Ph.Eur. 9 th Ed., Suppl. 9.2 (0262) Anisi aetheroleum° Anise oil Anisi fructus° Aniseed Anisi stellati aetheroleum° Star anise oil Anisi stellati fructus° Star anise Anisolie Anise oil Ph.Eur.
Load more

Recommended publications
  • Compositions Comprising Drospirenone Molecularly
    (19) & (11) EP 1 748 756 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) A61K 9/107 (2006.01) 29.04.2009 Bulletin 2009/18 A61K 9/48 (2006.01) A61K 9/16 (2006.01) A61K 9/20 (2006.01) A61K 9/14 (2006.01) (2006.01) (2006.01) (21) Application number: 05708751.2 A61K 9/70 A61K 31/565 (22) Date of filing: 10.03.2005 (86) International application number: PCT/IB2005/000665 (87) International publication number: WO 2005/087194 (22.09.2005 Gazette 2005/38) (54) COMPOSITIONS COMPRISING DROSPIRENONE MOLECULARLY DISPERSED ZUSAMMENSETZUNGEN AUS DROSPIRENON IN MOLEKULARER DISPERSION DES COMPOSITIONS CONTENANT DROSPIRENONE A DISPERSION MOLECULAIRE (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • FUNKE, Adrian HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR D-14055 Berlin (DE) Designated Extension States: • WAGNER, Torsten AL BA HR MK YU 13127 Berlin (DE) (30) Priority: 10.03.2004 EP 04075713 (74) Representative: Wagner, Kim 10.03.2004 US 551355 P Plougmann & Vingtoft a/s Sundkrogsgade 9 (43) Date of publication of application: P.O. Box 831 07.02.2007 Bulletin 2007/06 2100 Copenhagen Ø (DK) (60) Divisional application: (56) References cited: 08011577.7 / 1 980 242 EP-A- 1 260 225 EP-A- 1 380 301 WO-A-01/52857 WO-A-20/04022065 (73) Proprietor: Bayer Schering Pharma WO-A-20/04041289 US-A- 5 569 652 Aktiengesellschaft US-A- 5 656 622 US-A- 5 789 442 13353 Berlin (DE) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • The Management of Common Skin Conditions in General Practice
    Management of Common Skin Conditions In General Practice including the “red rash made easy” © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care University of Auckland, Tamaki Campus Reviewed by Hon A/Prof Amanda Oakley - 2019 http://www.dermnetnz.org Management of Common Skin Conditions In General Practice Contents Page Derm Map 3 Classic location: infants & children 4 Classic location: adults 5 Dermatology terminology 6 Common red rashes 7 Other common skin conditions 12 Common viral infections 14 Common bacterial infections 16 Common fungal infections 17 Arthropods 19 Eczema/dermatitis 20 Benign skin lesions 23 Skin cancers 26 Emergency dermatology 28 Clinical diagnosis of melanoma 31 Principles of diagnosis and treatment 32 Principles of treatment of eczema 33 Treatment sequence for psoriasis 34 Topical corticosteroids 35 Combination topical steroid + antimicrobial 36 Safety with topical corticosteroids 36 Emollients 37 Antipruritics 38 For further information, refer to: http://www.dermnetnz.org And http://www.derm-master.com 2 © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care, University of Auckland, Tamaki Campus. Management of Common Skin Conditions In General Practice DERM MAP Start Is the patient sick ? Yes Rash could be an infection or a drug eruption? No Insect Bites – Crop of grouped papules with a central blister or scab. Is the patient in pain or the rash Yes Infection: cellulitis / erysipelas, impetigo, boil is swelling, oozing or crusting? / folliculitis, herpes simplex / zoster. Urticaria – Smooth skin surface with weals that evolve in minutes to hours. No Is the rash in a classic location? Yes See our classic location chart .
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Treatment of Diseases and Conditions Mediated By
    (19) TZZ_ ___T (11) EP 1 572 115 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 38/07 (2006.01) A61K 38/08 (2006.01) 21.01.2015 Bulletin 2015/04 A61K 38/17 (2006.01) A61K 38/38 (2006.01) (21) Application number: 03799853.1 (86) International application number: PCT/US2003/037901 (22) Date of filing: 25.11.2003 (87) International publication number: WO 2004/050023 (17.06.2004 Gazette 2004/25) (54) TREATMENT OF DISEASES AND CONDITIONS MEDIATED BY INCREASED PHOSPHORYLATION BEHANDLUNG VON ERKRANKUNGEN UND ZUSTÄNDEN,DIE DURCH ERHÖHTE PHOSPHORYLIERUNG VERMITTELT WERDEN TRAITEMENT DE MALADIES ET D’ETATS A MEDIATION DE PHOSPHORYLATION ACCRUE (84) Designated Contracting States: • JIANG B ET AL: "Phosphopeptides derived from AT BE BG CH CY CZ DE DK EE ES FI FR GB GR hen egg yolk phosvitin: effect of molecular size HU IE IT LI LU MC NL PT RO SE SI SK TR on the calcium-binding properties." BIOSCIENCE, BIOTECHNOLOGY, AND (30) Priority: 27.11.2002 US 429924 P BIOCHEMISTRY MAY 2001, vol. 65, no. 5, May 2001 (2001-05), pages 1187-1190, XP002549556 (43) Date of publication of application: ISSN: 0916-8451 14.09.2005 Bulletin 2005/37 • KATAYAMA SHIGERU ET AL: "Antioxidative stress activity of oligophosphopeptides derived (73) Proprietor: Ampio Pharmaceuticals, Inc. from hen egg yolk phosvitin in Caco-2 cells." Englewood, CO 80112 (US) JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 8 FEB 2006, vol. 54, no. 3, 8 February (72) Inventor: BAR-OR, David 2006 (2006-02-08), pages 773-778, XP002549557 Englewood, CO 80110 (US) ISSN: 0021-8561 • OKAMOTO ET AL: ’The interleukin-8 AP-1 and (74) Representative: Weber, Joachim kappa B-like sites are genetic end targets of Hoefer & Partner FK506-sensitive pathway accompanied by Patentanwälte calcium mobilization.’ JOURNAL OF Pilgersheimer Strasse 20 BIOLOGICAL CHEMISTRY vol.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,828,435 B2 Hewitt Et Al
    USOO88284.35B2 (12) United States Patent (10) Patent No.: US 8,828,435 B2 Hewitt et al. (45) Date of Patent: Sep. 9, 2014 (54) BUCCAL DELIVERY SYSTEM 2002/0114833 A1 8/2002 Abu-IZZa et al. 2004/0019026 A1 1/2004 Schwartz ...................... 514,177 2004/0028732 A1 2/2004 Falkenhausen et al. (75) Inventors: Ernest Alan Hewitt, Windsor Downs 2004/0037878 A1 2/2004 Szamosi et al. (AU); Richard James Stenlake, Double 2006, O141027 A1 6, 2006 Cioli Day (AU) FOREIGN PATENT DOCUMENTS (73) Assignee: Lingual Consegna Pty Ltd (AU) EP 215635 3, 1987 (*) Notice: Subject to any disclaimer, the term of this GB 1248.189 9, 1971 patent is extended or adjusted under 35 W. wo: iii. U.S.C. 154(b) by 85 days. WO WO9904758 2, 1999 WO WOO189485 11, 2001 (21) Appl. No.: 13/021,578 WO 2004075877 A1 9, 2004 (22) Filed: Feb. 4, 2011 OTHER PUBLICATIONS (65) Prior Publication Data Velaz I., et al., “Effect of PEG 4000 on the Dissolution Rate of Naproxen”, European Journal of Drug Metabolism & US 2011 FO123619 A1 May 26, 2011 Pharmacokinetics, vol. 23, No. 2, pp. 103-108 (Apr.-Jun. 1998). Runkel, R., et al., "Naproxen Oral Absorption Characteristics'. Related U.S. Application Data Chem. Pharm. Bull. vol. 70, No. 7, pp. 1457-1466 (197p). Ranucci E. et al., “Pharmacokinetic Results on Naproxen Prodrugs (63) Continuation of application No. 1 1/910.902, filed as Based on Poly(ethyleneglycol)s', J Biomater Sci Polymer Edn, vol. application No. PCT/AU2006/000472 on Apr. 7, 2006, 6, No.
    [Show full text]
  • Labeling and Synthesis of Estrogens and Their Metabolites
    Labeling and Synthesis of Estrogens and Their Metabolites Paula Kiuru University of Helsinki Faculty of Science Department of Chemistry Laboratory of Organic Chemistry P.O. Box 55, 00014 University of Helsinki, Finland ACADEMIC DISSERTATION To be presented with the permission of the Faculty of Science of the University of Helsinki, for public criticism in Auditorium A110 of the Department of Chemistry, A. I. Virtasen Aukio 1, Helsinki, on June 18th, 2005 at 12 o'clock noon Helsinki 2005 ISBN 952-91-8812-9 (paperback) ISBN 952-10-2507-7 (PDF) Helsinki 2005 Valopaino Oy. 1 ABSTRACT 3 ACKNOWLEDGMENTS 4 LIST OF ORIGINAL PUBLICATIONS 5 LIST OF ABBREVIATIONS 6 1. INTRODUCTION 7 1.1 Nomenclature of estrogens 8 1.2 Estrogen biosynthesis 10 1.3 Estrogen metabolism and cancer 10 1.3.1 Estrogen metabolism 11 1.3.2 Ratio of 2-hydroxylation and 16α-hydroxylation 12 1.3.3 4-Hydroxyestrogens and cancer 12 1.3.4 2-Methoxyestradiol 13 1.4 Structural and quantitative analysis of estrogens 13 1.4.1 Structural elucidation 13 1.4.2 Analytical techniques 15 1.4.2.1 GC/MS 16 1.4.2.2 LC/MS 17 1.4.2.3 Immunoassays 18 1.4.3 Deuterium labeled internal standards for GC/MS and LC/MS 19 1.4.4 Isotopic purity 20 1.5 Labeling of estrogens with isotopes of hydrogen 20 1.5.1 Deuterium-labeling 21 1.5.1.1 Mineral acid catalysts 21 1.5.1.2 CF3COOD as deuterating reagent 22 1.5.1.3 Base-catalyzed deuterations 24 1.5.1.4 Transition metal-catalyzed deuterations 25 1.5.1.5 Deuteration without catalyst 27 1.5.1.6 Halogen-deuterium exchange 27 1.5.1.7 Multistep labelings 28 1.5.1.8 Summary of deuterations 30 1.5.2 Enhancement of deuteration 30 1.5.2.1 Microwave irradiation 30 1.5.2.2 Ultrasound 31 1.5.3 Tritium labeling 32 1.6 Deuteration estrogen fatty acid esters 34 1.7 Synthesis of 2-methoxyestradiol 35 1.7.1 Halogenation 35 1.7.2 Nitration of estrogens 37 1.7.3 Formylation 38 1.7.4 Fries rearrangement 39 1.7.5 Other syntheses of 2-methoxyestradiol 39 1.7.6 Synthesis of 4-methoxyestrone 40 1.8 Synthesis of 2- and 4-hydroxyestrogens 41 2.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,044,466 B2 Cohen Et Al
    USOO9044466B2 (12) United States Patent (10) Patent No.: US 9,044,466 B2 Cohen et al. (45) Date of Patent: *Jun. 2, 2015 (54) ORAL COMPOSITIONS COMPRISINGA 2800/882 (2013.01); A61O II/00 (2013.01); ZINC COMPOUND AND AN A61K 45/06 (2013.01); A61 K47/02 (2013.01); ANT-MICROBAL AGENT (Continued) (58) Field of Classification Search (75) Inventors: Marvin Cohen, St. Louis, MO (US); CPC ...... A61K 8/27; A61 K33/30; A61K 31/4425 Susanne Cohen, St. Louis, MO (US); USPC ............................................................ 424/49 Robert G. Flynn, Dupo, IL (US) See application file for complete search history. (73) Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF (56) References Cited NEW YORK, Albany, NY (US) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this 4,226,851 A 10/1980 Sompayrac patent is extended or adjusted under 35 4,692,262 A 9, 1987 Brown et al. U.S.C. 154(b) by 0 days. (Continued) This patent is Subject to a terminal dis claimer. FOREIGN PATENT DOCUMENTS CN 101780016 A T 2010 (21) Appl. No.: 13/204,595 WO WO-OOf 51559 A1 9, 2000 (22) Filed: Aug. 5, 2011 (Continued) OTHER PUBLICATIONS (65) Prior Publication Data International Preliminary Report on Patentability for International US 2012/003428O A1 Feb. 9, 2012 Application No. PCT/US2011/046831 dated Feb. 21, 2013. Related U.S. Application Data (Continued) (60) Provisional application No. 61/371,695, filed on Aug. Primary Examiner – Rachael E. Bredefeld 7, 2010, provisional application No. 61/371,696, filed (74) Attorney, Agent, or Firm — Harness, Dickey & Pierce, on Aug.
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • Taking a Dermatological Approach to Treating Ocular Surface Diseases
    Taking a Dermatological Approach to treating Ocular Surface Diseases MARC GLEESON | CHIEF EXECUTIVE OFFICER OIS@SECO 2020 for Meibomian Gland Dysfunction, Contact Lens Discomfort & Blepharitis Copyright© Azura Ophthalmics | Confidential Meibomian Gland Contact Lens Blepharitis Demodex Dysfunction Discomfort Patient Administered Patient Administered Patient Administered Rx Proven activity against Rx Chronic Treatment Rx Chronic Treatment Treatment applied to Demodex applied to the eyelid applied to the eyelid the eyelid Allows continuation of New Chemical Entity In Office Physician Only Contact Lens Wear Administered Rx Treatment Lid Margin Involvement Hyperkeratinization of the Gland Orifice +/- Inflammation Copyright© Azura Ophthalmics | Confidential (MGD) Reduced secretion of lipids leads to instability of the tear film Modified sebaceous (oil-producing) and drying of the ocular surface, leading to damage and the glands responsible for secreting the signs and symptoms of dry eye disease (DED). outer lipid layer (meibum) of the tear film, which lubricates the ocular Obstructive MGD is the most common cause of evaporative surface during blinking and protects dry DED,1,3 and clinical signs of obstructive MGD are present against tear evaporation1,2 in 86% of DED patients4 MGD traditionally regarded as a hypersecretory disorder associated with bacterial infection and inflammation,1 which has guided the approach to treatment, often unsuccessfully 1Blackie et al. Cornea. 2010 | 2Knop et al. Invest Ophthalmol Vis Sci. 2011 | 3Baudouin et al.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • AX Pharmaceutical Corp Product List
    AX Pharmaceutical Corp Product List A 4-Aminopyridine Acetazolamine ACTH 1-24 Acyclovir Sodium Adenosine 5 Monophosphate Adenosine 5 Tri-Phosphate Disodium Salt Albendazole Alendronate Sodium USP Alternogest Aminopentamide Sulfate Aminophylline Amlodipine Besylate Amoxicillin/Clavulanate Potassium 4:1 Amoxicillin Trihydrate Amphotericin B Ampicillin Anastrozole Aripepazole Aripiprazole Atipamezole HCl Atovaquone USP Atropine Sulfate Monohydrate Avanafil Azelastine HCl B Baclofen Benazepril HCl Betahistine Dihydrochloride Betaine Hydrochloride Betamethasone Acetate Betamethasone Dipropionate Betamethasone Sodium Phosphate Betaxolol Bexarotene Bicalutamide Bimatoprost Bisacodyl Bismuth Subcarbonate Bismuth Subsalicylate Bleomycin A5 Hydrochloride Bleomycin Sulfate Bretylium Tosylate Brimonidine Brinzolamide Bromhexine Bromocriptine Mesylate Brompheniramine Maleate Budesonide Bumetanide Bupivacaine Base Bupivacaine Hydrochloride Buprenorphine Bupropion HCl Buspirone Hydrochloride Busulfan Butaphosphan Butylated Hydroxyanisole C Cabergoline Calamine Calcium Glycerophosphate Calcium Levulinate Dihydrate Capsaicin Captopril Carbamazepine Carbazochrome Carbenoxolone Carbetocin Acetate Carbidopa Carbocisteine Carboplatin Carmustine Carprofen Carvedilol Cefadroxil Hemihydrate Cefadroxil Monohydrate Cefazolin Cefazolin Sodium Cefdinir Cefotaxime Cefotetan Disodium Cefpodoxime Cefpodoxime Proxetil Ceftazidime Ceftiofur Free Acid Ceftiofur Sodium Ceftriaxone Cefuroxime (Ceftin) Celecoxib Cephalexin Base Cephalexin Monohydrate Cesium Chloride Cetirizine
    [Show full text]